NASDAQ : CRVO

CervoMed Inc. — Company profile

Healthcare · Biotechnology · United States

Last price 1.75 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 26.46M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Company profile

CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. The company is developing neflamapimod, an orally administered small molecule drug that crosses the blood–brain barrier and inhibits the enzyme p38α. Neflamapimod has the potential to reverse synaptic dysfunction, improve neuron health, and slow or prevent disease progression. Neflamapimod is currently in clinical development for the treatment of dementia with Lewy bodies, non-fluent variant primary progressive aphasia, amyotrophic lateral sclerosis, and amyotrophic lateral sclerosis. CervoMed Inc. was founded in 2010 and is headquartered in Boston, Massachusetts.

Details

NameCervoMed Inc.
SectorHealthcare
IndustryBiotechnology
Employees15
Founded2001
CeoJohn Alam
CountryUnited States
ExchangeNASDAQ
Fiscal YearJanuary - December
Reporting CurrencyUSD
IsinUS15713L1098
Cusip15713L109
Cik0001053691
Sic2834

Key executives

NameTitle
Dr. John J. Alam M.D.Co-Founder, Chief Executive Officer, President and Director
Dr. Sylvie L. Gregoire Pharm.D.Co-Founder and Director
William Robert Elder J.D.Chief Financial Officer, General Counsel and Corporate Secretary
Kelly Blackburn M.H.A.Executive Vice President of Clinical Development
Dr. Marinus Verwijs Ph.D.Executive Vice President of Technical Operations
Dr. Mark A. De Rosch Ph.D.Executive Vice President of Regulatory, Government Affairs and Program Management
Dr. Claudia Ordonez M.D.Senior Vice President of Medical Science
Dr. Matthew Winton Ph.D.Chief Commercial and Business Officer

Contact

Address20 Park Plaza, Suite 424, Boston, Massachusetts 02116, United States
Phone617 744 4400
Websitehttps://www.cervomed.com